Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

On Dec 27, Zacks Investment Research upgraded Laboratory Corporation of America Holdings (LH - Analyst Report) to a Zacks Rank #3 (Hold).

Why the Upgrade?

LabCorp’s prelim 2014 earnings projection, declared on Dec 11, disappointed majority of the investors, leading to significant loss in share price in the last two weeks. For 2014, the company expects to post adjusted earnings per share (EPS) excluding amortization of $6.50, 16% below the Zacks Consensus Estimate of $7.56 a share.

Keeping in mind the challenging operating environment, the company anticipates feeble revenue growth (of mere 2%) in the upcoming fiscal. The current Zacks Consensus Estimate for revenues stands at $5,939 million, ahead of the company’s expectation.

With the stock price at its current low, we do not expect any further downward rally as the impact of the disappointing outlook has already taken shape. Moreover, we are upbeat about the company’s focus on portfolio expansion to drive the top line. The company is banking more on the high-margin esoteric testing business, which is expected to contribute 45% of total sales in the next 3–5 years.

In addition, the acquisition pipeline and partnerships remain attractive. The company’s recent acquisition of Medtox Scientific will help strengthen the company’s foothold in specialized toxicology testing.Early this year, the company announced that Bristol-Myers Squibb (BMY - Analyst Report) entered into a 5-year agreement to select LabCorp Clinical Trials as a preferred provider for full-service global central laboratory services and biomarker testing.

Other Stocks to Consider

Better-ranked stocks in the technology sector include Align Technology Inc. (ALGN - Analyst Report) and McKesson Corp. (MCK - Analyst Report). While Align carries a Zacks Rank #1 (Strong Buy), McKesson holds a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%